{"id":413,"date":"2013-05-17T12:31:19","date_gmt":"2013-05-17T10:29:13","guid":{"rendered":"http:\/\/semmelweis-egyetem.hu\/immun-patofiziologia\/?page_id=413"},"modified":"2024-01-10T13:16:12","modified_gmt":"2024-01-10T12:16:12","slug":"grants","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/immun-patofiziologia\/en\/research\/grants\/","title":{"rendered":"Grants"},"content":{"rendered":"

Current Grants:<\/strong><\/span><\/p>\n

2024-2027<\/em>,\u00a0OTKA_K<\/strong>, Inhibition of protective mechanisms (local heat shock and stress protein production) during breast cancer treatment to enhance the effectiveness of chemotherapy and hyperthermia treatment<\/p>\n

\n

2023,\u00a0STIA-Mec (Semmelweis University) <\/strong>Tumor- targeting drug delivery<\/p>\n

\n

2023,\u00a0STIA-Mec (Semmelweis University) <\/strong>The role of tumor inflammation in the pathomechanism and treatment of breast cancer.<\/p>\n

\n

2023,\u00a0STIA-Mec (Semmelweis University)<\/strong>\u00a0Enhancement of Modulated Electro-Hyperthermia (mEHT) Effects by Heat Shock Factor 1 (HSF1) Inhibition in Triple Negative Breast Cancer (TNBC) Mouse Model<\/p>\n

\n

2023,\u00a0STIA-Mec (Semmelweis University)<\/strong>\u00a0Enhancement of Modulated Electro-Hyperthermia (mEHT) Effects by Heat Shock Factor 1 (HSF1) Inhibition in Triple Negative Breast Cancer (TNBC) Mouse Model<\/p>\n

\n

2023<\/em>,\u00a0STIA-OTKA (Semmelweis University)<\/strong>, Inhibiting cancer self-protective mechanisms (local heat-shock response) to enhance the effectivity of established anti-cancer
\ntherapies (chemotherapy and hyperthermia)<\/p>\n

\n

2023-2025<\/em>, T\u00e9T<\/strong>, H\u00e1romszoros negat\u00edv eml\u0151r\u00e1k n\u00f6veked\u00e9s\u00e9nek g\u00e1tl\u00e1sa eg\u00e9r-modellen. A modul\u00e1lt elektro-hipertermia (mEHT) hat\u00e1s\u00e1nak fokoz\u00e1sa thermosensitive liposz\u00f3ma seg\u00edts\u00e9g\u00e9vel t\u00f6rt\u00e9n\u0151 doxorubicin, h\u0151sok faktor-1 vagy a progeszteron receptor g\u00e1tl\u00e1s\u00e1val.<\/p>\n

\n

2022-2023<\/em>, \u00daNKP<\/strong>, Elektro-hiperthermia molekul\u00e1ris hat\u00e1sainak \u00e9s tumorsejtek v\u00e9dekez\u0151 mechanizmusainak vizsg\u00e1lata eg\u00e9r eml\u0151r\u00e1k modellben.<\/p>\n

\n

2020-2024<\/em>, OTKA_K<\/strong>, Sziszt\u00e9m\u00e1s \u00e9s lok\u00e1lis gyullad\u00e1s \u00e1ltal induk\u00e1lt hiperakt\u00edv h\u00f3lyag szindr\u00f3ma etiol\u00f3gi\u00e1ja – az izoproszt\u00e1nok szerepe<\/p>\n

\n

 <\/p>\n

 <\/p>\n

Outdated Grants:<\/strong><\/span><\/p>\n

\n

2021-2022<\/em>, \u00daNKP (\u00daj Nemzeti Kiv\u00e1l\u00f3s\u00e1g Program),<\/strong> Stressz-asszoci\u00e1lta molekul\u00e1k szerepe az eml\u0151r\u00e1k patomechanizmus\u00e1ban \u00e9s kezel\u00e9s\u00e9ben.<\/p>\n

\n

2017-2020<\/em>, NVKP (National Competitiveness and Excellency Program)<\/strong>, Impoving the efficency and market introduction of electromagnetic cancer therapy equipment (1500 million Ft)<\/p>\n

\n

2015-2019<\/em>, OTKA-SNN (Collaborative Grant with Slovenia)<\/a>, The role of micro RNA-21 and cathepsins in delayed preconditioning to acute kidney injury (2\u00d730 million Ft)<\/p>\n

\n

2014-2018<\/em>, OTKA-ANN (Collaborative Grant with Austria)<\/strong>, Micro-RNAs and renal fibrotic damage in stroma and glomeruli: Ischemia-reperfusion-induced fibrosis and focal segmental glomerulosclerosis (2\u00d730 million Ft)<\/p>\n

\n

2010-2014<\/em>, OTKA (K81972)<\/a><\/strong>, Regulatory role of micro RNA networks in acute renal failure<\/a><\/p>\n

\n

2009-2011<\/em>, ETT (07-011\/ 2009)<\/strong>, Micro RNS h\u00e1l\u00f3zatok szab\u00e1lyoz\u00f3 szerep\u00e9nek vizsg\u00e1lata akut veseel\u00e9gtelens\u00e9gben.<\/p>\n

\n

2008-2010<\/em>, OTKA NF (69278)<\/a><\/strong>, The role of TGF-beta and its intracellular signaling in uremic atherosclerosis<\/a><\/p>\n

\n

2007-2008<\/em>, OMFB\/Tet (\u00d6AD HU\/08\/2007)<\/strong>, The role of lymphangioneogenesis in chronic allograft nephropathy<\/p>\n

\n

2007-2008<\/em>, OMFB\/Tet (DAAD D\/06\/05860)<\/strong>, Combined inhibition of Aldosteron and RAS systems in 5\/6 nephrectomy model of renal fibrosis<\/p>\n

\n

2006-2008<\/em>, Else Kr\u00f6ner-Fresenius Stiftung)<\/strong>, Einflu\u00df der kombinierten Blockade von RAS und Mineralkortikoid Rezeptor auf die Progressionam Modell der subtotalen Nephrektomie- morphologische und molekularbiologische Untersuchungen<\/p>\n

\n

2005<\/em>, Asb\u00f3th Oszk\u00e1r program DermaVir projekt (HIKC05\/2005)<\/strong>, Az \u00e9relmeszesed\u00e9s befoly\u00e1sol\u00e1sa T-sejt v\u00e1laszt m\u00f3dos\u00edt\u00f3 DNS vakcin\u00e1l\u00e1si elj\u00e1r\u00e1s seg\u00eds\u00e9g\u00e9vel<\/p>\n

\n

2005-2008<\/em>, Fogarthy International and Cooperative Projects (FIRCA R03 TW007069-01A1)<\/strong>, RNAi to limit kidney ischemia\/reperfusion injury<\/p>\n

\n

2005-2009<\/em>, OTKA (T049022)<\/strong>, Vese ischemia\/reperf\u00fazi\u00f3s k\u00e1rosod\u00e1s\u00e1nak g\u00e1tl\u00e1sa RNS interferencia seg\u00edts\u00e9g\u00e9vel<\/p>\n

\n

2005-2006<\/em>, OMFB\/Tet – K\u00edna(CHN-37\/04)<\/strong>, Limiting ischemia\/reperfusion injury of the kidney utilising siRNA mediated gene silencing.<\/p>\n

\n

2004-2005<\/em>, OMFB\/Tet -DAAD (D-6)<\/strong>, Terhess\u00e9g hat\u00e1sa sziszt\u00e9m\u00e1s autoimmun betegs\u00e9g lefoly\u00e1s\u00e1ra MRL\/lpr egerekben<\/p>\n

\n

2004<\/em>, DAAD M\u0171sze<\/strong>r, Equippment grant for implantable telemetric device<\/p>\n

\n

2004<\/em>, OMFB\/Tet – K\u00edna(CHN-10\/03 )<\/strong>, The role of cytotoxic T-lymphocytes and FAS mediated apoptosis in kidney graft rejection, lupus nephritis and circulatory shock<\/p>\n

\n

2003-2005<\/em>, ETT (432\/2003)<\/strong>, A citotoxikus T-limfocit\u00e1k \u00e9s a FAS molekula szerepe vese\u00e1t\u00fcltet\u00e9st k\u00f6vet\u0151 kil\u00f6k\u0151d\u00e9si reakci\u00f3ban \u00e9s lupus nefritisben<\/p>\n

\n

2003<\/em>, Data Sciences International (DSI-TAG)<\/strong>, Educational grant for implantable telemetric physiological monitoring<\/p>\n

\n

2002<\/em>, OTKA M\u0171szer (M036969)<\/strong>, Implant\u00e1lhat\u00f3 telemetri\u00e1s m\u00e9r\u0151m\u0171szer, intravit\u00e1lis kering\u00e9is param\u00e9terek monitoroz\u00e1s\u00e1ra \u00e9ber \u00e1llaton<\/p>\n

\n

2002<\/em>, Magyar Nefrol\u00f3giai T\u00e1rsas\u00e1g<\/strong>, Pro-fibrotikus faktorok expresszi\u00f3j\u00e1nak vizsg\u00e1lata vesefibr\u00f3zis patk\u00e1nymodellj\u00e9n<\/p>\n

\n

2001-2004<\/em>, OTKA (F034498)<\/strong>, A T-limfocit\u00e1k progressz\u00edv glomeruloszkler\u00f3zisban bet\u00f6lt\u00f6tt szerepe<\/p>\n

\n

2001-2004<\/em>, OM B\u00e9k\u00e9sy Gy\u00f6rgy posztdoktori \u00f6szt\u00f6nd\u00edj(B\u00d6 121\/2001)<\/strong>, A T-limfocit\u00e1k, \u00e9s a transzform\u00e1l\u00f3 n\u00f6veked\u00e9si faktor-b (TGF-b) szerep\u00e9nek vizsg\u00e1lata kr\u00f3nikus vesebetegs\u00e9gben \u00e9s kr\u00f3nikus vese allograft nefrop\u00e1ti\u00e1ban, patk\u00e1nymodellen.<\/p>\n

\n

2001<\/em>, Magyar Hypert\u00f3nia T\u00e1rsas\u00e1g<\/strong>, Kr\u00f3nikus allograft nefrop\u00e1tia \u00e9s a sziszt\u00e9m\u00e1s v\u00e9rnyom\u00e1s \u00f6sszef\u00fcgg\u00e9seinek vizsg\u00e1lata<\/p>\n

\n

2000-2002<\/em>, ETT (225\/2000)<\/strong>, A T-limfocit\u00e1k progressz\u00edv glomeruloszkler\u00f3zisban bet\u00f6lt\u00f6tt szerepe<\/p>\n

\n

2000-2001<\/em>, MTA Bolyai J\u00e1nos \u00f6szt\u00f6nd\u00edj (BO\/00175\/00)<\/strong>, A T-limfocit\u00e1k progressz\u00edv glomeruloszkler\u00f3zisban bet\u00f6lt\u00f6tt szerepe<\/p>\n

\n

2000<\/em>, Magyar Nefrol\u00f3giai T\u00e1rsas\u00e1g<\/strong>, A T-limfocit\u00e1k progressz\u00edv glomeruloszkler\u00f3zisban bet\u00f6lt\u00f6tt szerepe<\/p>\n

\n

1999-2002<\/em>, OMFB\/Tet-BMFB (D-39\/99)<\/strong>, Az interleukin-2 \u00e1ltal aktiv\u00e1lt T-limfocit\u00e1k progressz\u00edv glomerulo- szkler\u00f3zisban bet\u00f6lt\u00f6tt szerepe.<\/p>\n

\n

1998-2000<\/em>, MTA Bolyai J\u00e1nos \u00f6szt\u00f6nd\u00edj (BO\/00322\/98)<\/strong>, A transzplant\u00e1lt vese akut kil\u00f6k\u0151d\u00e9s\u00e9nek vizsg\u00e1lata patk\u00e1nyon<\/p>\n

\n

1998<\/em>, Magyar Nefrol\u00f3giai T\u00e1rsas\u00e1g<\/strong>, Transzplant\u00e1lt vese akut kil\u00f6k\u0151d\u00e9s\u00e9nek vizsg\u00e1lata<\/p>\n

\n

1997-1999<\/em>, OTKA (F024040)<\/strong>, A kr\u00f3nikus kil\u00f6k\u0151d\u00e9s patomechanizmus\u00e1nak vizsg\u00e1lata, vesetranszplant\u00e1lt patk\u00e1nymodellen.<\/p>\n","protected":false},"excerpt":{"rendered":"

Current Grants: 2024-2027,\u00a0OTKA_K, Inhibition of protective mechanisms (local heat shock and stress protein production) during breast cancer treatment to enhance the effectiveness of chemotherapy and hyperthermia treatment 2023,\u00a0STIA-Mec (Semmelweis University) Tumor- targeting drug delivery 2023,\u00a0STIA-Mec (Semmelweis University) The role of tumor inflammation in the pathomechanism and treatment of breast cancer. 2023,\u00a0STIA-Mec (Semmelweis University)\u00a0Enhancement of Modulated …<\/p>\n","protected":false},"author":162,"featured_media":0,"parent":372,"menu_order":1,"comment_status":"closed","ping_status":"open","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-413","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/pages\/413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/users\/162"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/comments?post=413"}],"version-history":[{"count":12,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/pages\/413\/revisions"}],"predecessor-version":[{"id":2278,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/pages\/413\/revisions\/2278"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/pages\/372"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/media?parent=413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/categories?post=413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/immun-patofiziologia\/wp-json\/wp\/v2\/tags?post=413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}